Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• semaglutide — DRUG
  One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
• exenatide — DRUG
  One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly

Study Details

This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.

Key Dates

Start date

Dec 2, 2013

Status verified

May 2019

Primary completion

Jul 13, 2015

Completion

Jul 13, 2015

Study Design

Enrollment

813 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Semaglutide 1.0 mg
• Active Comparator: Exenatide ER 2.0 mg

Primary Outcome Measure

Change From Baseline in HbA1c (Glycosylated Haemoglobin) [ Time Frame: Week 0, week 56 ]

Locations (76)

Find similar trials in Anniston, AL

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Urinary Vitamin C Loss in Diabetic Subjects
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations
  Enrolling By Invitation · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland